The most reassuring idea in the peptide world is that a GH secretagogue is safe because it’s pulsatile — a brief signal that comes and goes, leaving troughs where the body can clean house. It’s half right, and the half that’s wrong is the half that matters. Pulsatility is a property of GH. It is not a property of IGF-1.
The pulsatility argument is genuinely appealing, and it’s the reason thoughtful people prefer a secretagogue over exogenous growth hormone. The reasoning goes: your own GH comes in short bursts with deep troughs between them, so an agent that stimulates your natural pulses respects that design — the signal is on for an hour, then off, and in the off-phase autophagy can run. Elegant. And for GH itself, entirely correct. But GH is not the molecule that carries most of the growth signal to your tissues, and it is not the molecule the longevity evidence points at. That molecule is IGF-1 — and IGF-1 does not pulse. Understanding why requires one piece of physiology that almost never makes it into these conversations, and once you have it, the whole debate reorganizes.
GH has a very short half-life. Pulses last minutes; between them, circulating GH falls to near-undetectable. That’s the spiky trace — and it’s real, and it’s the shape a GHRH analog preserves.
But GH’s main job isn’t to act on your tissues directly. It’s to instruct your liver to make IGF-1, and the liver does something specific with those pulses: it integrates them. Spikes go in; a steady, elevated tone comes out. In engineering terms the liver is a low-pass filter — it strips the high-frequency structure and passes the average. Your tissues never see the pulses. They see the average, sustained around the clock.
The reason IGF-1 can’t pulse is beautifully concrete. Over 99% of circulating IGF-1 is not free — it’s locked in a ternary complex with IGFBP-3 and ALS (acid-labile subunit). That assembly is too large to leave the bloodstream. It can’t exit the capillaries and it can’t be cleared quickly, so it sits in circulation as a reservoir, buffering every pulse into a steady tone. Free IGF-1 would indeed vanish in minutes — but almost none of it is free. The bound fraction has a half-life of roughly 12 to 15 hours.
Here’s a test you can run on any program that recommends a GH secretagogue. Look at how they monitor it: they draw IGF-1, once, at a convenient time, to confirm response. That only works if IGF-1 is a stable analyte — a random draw would be meaningless for something that came and went within the hour. The fact that IGF-1 is the standard marker of GH status is itself proof that it doesn’t pulse. The protocol’s own monitoring plan refutes the protocol’s own pulsatility reassurance.
So the reassurance needs narrowing — honestly, and in both directions.
What pulsatility genuinely buys. GH’s direct effects — lipolysis above all — depend on pulse shape; a pulsed signal drives fat breakdown in a way a flat one doesn’t. It avoids receptor desensitization. And crucially it keeps negative feedback intact, so the system can still self-limit rather than being overridden. These are real advantages, and they are why a secretagogue is meaningfully preferable to exogenous GH. That part of the argument survives.
What it doesn’t buy. It does not protect the IGF-1 arm — because the IGF-1 arm has no troughs to protect. And that is precisely the arm the longevity evidence indicts: Laron syndrome is IGF-1 deficiency; the long-lived dwarf mice have broken GH→IGF-1 signaling; the cancer associations are IGF-1 associations. So “the troughs let autophagy breathe” applies to GH’s direct signaling, not to the tonic IGF-1 elevation that runs for the entire cycle. Pulsatility buys less than the pitch implies — and less than a casual mechanistic reading suggests.
Two things genuinely support the instinct that some GH/IGF-1 signaling is good.
Restoration versus enhancement. Exactly as with testosterone: restoring an age-declined pulse pattern toward a youthful physiological range is a different intervention from pushing supraphysiological. Same molecule, different halves of the curve.
Human IGF-1 is probably U-shaped. Very low IGF-1 in older adults tracks with frailty, sarcopenia, and higher mortality. “Less is always better” holds in mice; it does not transfer cleanly to humans. There is plausibly a middle — which means the honest position is neither “IGF-1 is youth” nor “IGF-1 is death.”
Everything turns on this, and it is genuinely open. The “somatopause” framing — the standard pitch — assumes the age-related decline in GH is a malfunction to be corrected, like failing eyesight. The alternative reading is that the decline is the body deliberately shifting from build mode toward maintain mode — doing exactly what it should — and that reversing it means overriding a program that may be working correctly. Nobody knows which is true. Anyone confident in either direction is ahead of the evidence, and the confident ones are usually selling something.
Here is where the whole thing resolves, and it lands on a distinction you’ve seen before. IGF-1 isn’t one thing — it comes in two varieties that share a name and almost nothing else.
Local IGF-1 is produced inside the muscle you just trained, acting autocrine/paracrine on its immediate neighbours. It’s transient, confined, self-limiting — a growth signal delivered exactly where mechanical work earned it. Systemic hepatic IGF-1 is made by the liver and poured into the blood, reaching every tissue you own, tonically, for the entire cycle — earned or not.
Resistance training gives you the first. A secretagogue gives you the second.
Yes — the local kind, where you earned it. That is what training already delivers, and it’s free of the systemic cost precisely because it’s compartmentalized. What an injection delivers is the other kind: hepatic, tonic, body-wide. The intuition was right about the biology and wrong about which molecule the intervention actually produces.
GH pulsatility, the IGFBP-3/ALS ternary complex, and IGF-1’s 12–15 hour half-life are textbook endocrinology. The integrator picture is not controversial — it’s just rarely mentioned in marketing.
Pulse-dependent lipolysis, avoidance of receptor desensitization, and preserved negative feedback are genuine reasons a secretagogue beats exogenous GH. Narrower than claimed, but real.
Probably U-shaped — low IGF-1 in older adults tracks with frailty and mortality, so the rodent “less is better” result doesn’t transfer cleanly. Where the optimum sits is unsettled.
Whether the age-related GH decline is a malfunction to reverse or a deliberate mode-shift to respect is unknown. Every confident answer in either direction outruns the data.
Pulsatility is a property of GH, not of IGF-1. GH pulses last minutes with real troughs — but the liver integrates those pulses like a low-pass filter, and over 99% of the resulting IGF-1 is locked in a ternary complex with IGFBP-3 and ALS, too large to leave the blood, giving it a 12–15 hour half-life. So your tissues never see an hour of signal — they see tonic IGF-1 elevation for the whole cycle. (The proof: every protocol measures IGF-1 with one convenient blood draw, which only works for a stable analyte.) Pulsatility genuinely buys pulse-dependent lipolysis, no receptor desensitization, and intact feedback — but it does not protect the IGF-1 arm, and IGF-1 is the arm the longevity data indicts (Laron is IGF-1 deficiency). What survives: restoration ≠ enhancement, human IGF-1 is probably U-shaped, and whether the age-related decline is a defect or an adaptation is genuinely unknown. And the resolution: there are two IGF-1s — local/autocrine from the muscle you trained (transient, confined, earned) and systemic/hepatic from an injection (tonic, body-wide, untargeted). A bit of IGF-1 is good for health. The local kind. Which training already gives you.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment, and does not recommend any compound, dose, or protocol for any individual. Tesamorelin and other GH-axis agents are prescription or unapproved compounds with significant effects, contraindications, and monitoring requirements, and are not appropriate for self-directed use. Pharmacokinetic figures are approximate population values that vary by individual, assay, age, and physiological state. The longevity implications discussed derive largely from animal models and rare human genetic conditions and may not generalize; no lifespan data exist for the agents named. Mechanisms described range from textbook physiology to genuinely open questions and are labelled accordingly. Decisions belong with a qualified physician who can assess your individual situation.
This lesson relates to these health systems — health works as a connected system, not isolated topics.